Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

ting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. In endometriosis, AIs act primarily by inhibiting local estradiol production inside the endometrial lesions. AIs are currently used for the chronic treatment of estrogen-dependent tumors in postmenopausal women and are being investigated in a variety of women's health conditions. Meditrina holds the exclusive worldwide rights to patent applications covering the use of AIs in gynecologic indications, including for endometrial thinning prior to hysteroscopic procedures.

About Meditrina Pharmaceuticals, Inc.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs. By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina's novel therapies have the potential to significantly alter the way these women's health conditions are treated. For more information about Meditrina Pharmaceuticals, please visit http://www.meditrina.com .

Meditrina Pharmaceuticals, Inc. Forward-Looking Statement Disclaimer

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, s
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 2012  BioParadox, Inc., a regenerative medicine company pioneering ... a strategic alliance with Fogarty Institute for Innovation.  ... working with the Fogarty Institute for Innovation known ... patients with challenging problems.  The Fogarty Institute,s unique ...
... 2, 2012 Synthetic Genomics, Inc. (SGI), a ... to solve a variety of global needs, and ... in production and supply of oligonucleotides, today jointly ... to manufacture, market, and commercialize small synthetic gene ...
Cached Medicine Technology:BioParadox Announces Partnership with Fogarty Institute for Innovation 2Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... CUR, QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two ... the detection of prostate cancer,and GCC for the staging ... part of the growing trend to molecular diagnostics., ... the 34th,Annual International Clinical Ligand Assay Society Meeting, held ...
... with whatever they could find, - Needs remain desperate for ... 250,000 survivors to date, but access ... challenges remain, YANGON, ... Nargis, many affected communities in Myanmar,s,Irrawaddy Delta are managing to survive and ...
... Personal Trainers For Peak ... Performance, LOS ANGELES, June 2 ... and Cher, now the,Pussycat Dolls are working out with Bally. On the verge ... video for,their hot new single "When I Grow Up," the Pussycat Dolls are ...
... Will Fund Chicago Latino Outreach Program and National Latino ... ... American Diabetes,Association (ADA) was recently awarded a $450,000 grant from Abbott ... Latino,Outreach Toolkit. Diabetes is an urgent health problem in the Latino,community. ...
... N.Y., June 2 Gentiva Health,Services, Inc. (Nasdaq: ... home health services, announced today that it has ... largest home health,providers, for $12 million in cash. ... facility., PHHC, first established by a group ...
... the risk, study finds , , MONDAY, June 2 (HealthDay News) ... increased risk for cancer recurrence, a Dana-Farber Cancer Institute study ... stage III colon cancer, and found that those with a ... years smoking times packs per day) were up to 22 ...
Cached Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Myanmar One Month Later: Delta Communities Surviving on Resilience 2Health News:Pussycat Dolls Shape Up With Bally Total Fitness 2Health News:American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 3Health News:Smokers With Colon Cancer Face High Recurrence Risk 2
... Slit Lamp features easy-to-use controls to help ... to a halogen bulb that gives up ... with powers of 10X and 16X, the ... accepts commercially available C-mount cameras, allowing physicians ...
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
Perfect for loading small volume samples onto agarose and polyacrylamide gels....
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Medicine Products: